Envista Holdings Co. (NYSE:NVST) Stake Increased by Franklin Resources Inc.

Franklin Resources Inc. lifted its holdings in Envista Holdings Co. (NYSE:NVST) by 72.6% in the 4th quarter, HoldingsChannel.com reports. The institutional investor owned 6,854,506 shares of the company’s stock after acquiring an additional 2,882,844 shares during the quarter. Franklin Resources Inc.’s holdings in Envista were worth $132,223,000 as of its most recent SEC filing.

Other large investors have also recently bought and sold shares of the company. Venturi Wealth Management LLC boosted its position in Envista by 528.4% during the 4th quarter. Venturi Wealth Management LLC now owns 1,948 shares of the company’s stock worth $38,000 after acquiring an additional 1,638 shares during the period. GAMMA Investing LLC boosted its holdings in shares of Envista by 30.5% during the fourth quarter. GAMMA Investing LLC now owns 2,304 shares of the company’s stock worth $44,000 after purchasing an additional 538 shares during the period. Thurston Springer Miller Herd & Titak Inc. purchased a new position in Envista during the fourth quarter valued at approximately $53,000. Mitsubishi UFJ Trust & Banking Corp purchased a new position in Envista during the fourth quarter valued at approximately $86,000. Finally, KBC Group NV increased its stake in Envista by 63.9% in the 4th quarter. KBC Group NV now owns 7,903 shares of the company’s stock valued at $152,000 after buying an additional 3,082 shares during the period.

Envista Trading Up 2.3 %

Envista stock opened at $17.49 on Thursday. The business’s 50-day simple moving average is $19.40 and its 200-day simple moving average is $19.57. Envista Holdings Co. has a 52 week low of $15.15 and a 52 week high of $23.00. The firm has a market capitalization of $3.01 billion, a PE ratio of -2.69, a PEG ratio of 1.27 and a beta of 1.33. The company has a debt-to-equity ratio of 0.44, a quick ratio of 1.76 and a current ratio of 2.04.

Envista (NYSE:NVST) last issued its quarterly earnings results on Wednesday, February 5th. The company reported $0.24 EPS for the quarter, topping analysts’ consensus estimates of $0.23 by $0.01. Envista had a positive return on equity of 3.86% and a negative net margin of 44.56%. Equities research analysts forecast that Envista Holdings Co. will post 1 earnings per share for the current year.

Analysts Set New Price Targets

Several research firms have recently commented on NVST. Jefferies Financial Group boosted their price target on shares of Envista from $20.00 to $22.00 and gave the company a “hold” rating in a report on Thursday, January 23rd. UBS Group lowered their target price on Envista from $23.00 to $21.00 and set a “neutral” rating on the stock in a research note on Monday, March 10th. Needham & Company LLC reaffirmed a “hold” rating on shares of Envista in a research note on Thursday, March 6th. New Street Research set a $19.00 price target on Envista in a research note on Thursday, March 6th. Finally, JPMorgan Chase & Co. cut their price objective on shares of Envista from $20.00 to $19.00 and set a “neutral” rating on the stock in a research report on Thursday, March 6th. Two investment analysts have rated the stock with a sell rating, ten have issued a hold rating and three have issued a buy rating to the company’s stock. According to data from MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus target price of $20.18.

Envista Company Profile

Envista Holdings Corporation, together with its subsidiaries, develops, manufactures, markets, and sells dental products in the United States, China, and internationally. The company operates in two segments, Specialty Products & Technologies, and Equipment & Consumables. The Specialty Products & Technologies segment offers dental implant systems, guided surgery systems, biomaterials, and prefabricated and custom-built prosthetics to oral surgeons, prosthodontists and periodontists, and general dentist; and brackets and wires, tubes and bands, archwires, clear aligners, digital orthodontic treatments, retainers, and other orthodontic laboratory products.